CYLD
CYLD (Ubiquitin carboxyl-terminal hydrolase CYLD) is an enzyme. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Bladder & urothelial cancer, Breast cancer, Colorectal cancer and 5 more.
Overview
Deubiquitinase that specifically cleaves 'Lys-63'- and linear 'Met-1'-linked polyubiquitin chains and is involved in NF-kappa-B activation and TNF-induced necroptosis. Negatively regulates NF-kappa-B activation by deubiquitinating upstream signalling factors. Contributes to the regulation of cell survival, proliferation and differentiation via its effects on NF-kappa-B activation.
Open Targets scores its association with cancer at 0.73 (direct and indirect evidence; datatypes literature 0.98, animal model 0.44, genetic association 0.02, somatic mutation 0.94). IntOGen calls it a driver in 11 cohorts (2 activating, 7 loss-of-function), covering Bladder Urothelial Carcinoma, Invasive Breast Carcinoma, Colorectal Adenocarcinoma, Head and Neck Squamous Cell Carcinoma, Nasopharyngeal Carcinoma, Non-Small Cell Lung Cancer and others.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · CYLD (Ubiquitin carboxyl-terminal hydrolase CYLD) is an enzyme. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Bladder & urothelial cancer, Breast cancer, Colorectal cancer and 5 more.
- 1 · What it is
CYLD (Ubiquitin carboxyl-terminal hydrolase CYLD) is an enzyme. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Bladder & urothelial cancer, Breast cancer, Colorectal cancer and 5 more.
- 2 · What goes wrong in cancer
Deubiquitinase that specifically cleaves 'Lys-63'- and linear 'Met-1'-linked polyubiquitin chains and is involved in NF-kappa-B activation and TNF-induced necroptosis.
- 3 · How drugs use it
No product in this corpus aims at CYLD yet. Inhibitors are shaped to fit the enzyme's active site so the reaction the cancer relies on stops.
External identifiers
Sources: HGNC HGNC:2584 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q9NQC7 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000083799 (association with cancer (MONDO_0004992) 0.73; per-cancer scores at or above 0.5: melanoma 0.58, skin cancer 0.57, thymic carcinoma 0.51 (GraphQL API, CC0)); IntOGen CYLD (driver in 11 cohorts (Act 2, LoF 7); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
Deubiquitinase that specifically cleaves 'Lys-63'- and linear 'Met-1'-linked polyubiquitin chains and is involved in NF-kappa-B activation and TNF-induced necroptosis. Negatively regulates NF-kappa-B activation by deubiquitinating upstream signalling factors. Contributes to the regulation of cell survival, proliferation and differentiation via its effects on NF-kappa-B activation. Negative regulator of Wnt signalling. Inhibits HDAC6 and thereby promotes acetylation of alpha-tubulin and stabilisation of microtubules. Plays a role in the regulation of microtubule dynamics, and thereby contributes to the regulation of cell proliferation, cell polarisation, cell migration, and angiogenesis. Location: Cytoplasm; Cytoplasm, perinuclear region; Cytoplasm, cytoskeleton; Cell membrane (UniProt). Locus 16q12.1 (HGNC).
- Bladder & urothelial cancer: IntOGen driver in 1 cohort (BLCA)
- Breast cancer: IntOGen driver in 1 cohort (BRCA)
- Colorectal cancer: IntOGen driver in 1 cohort (COADREAD)
- Head and neck squamous cell carcinoma: IntOGen driver in 1 cohort (HNSC)
- Nasopharyngeal carcinoma: IntOGen driver in 1 cohort (NPC)
- Multiple myeloma: IntOGen driver in 1 cohort (PCM)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it an activating (Act) driver in 2 cohorts; IntOGen calls it a loss-of-function (LoF) driver in 7 cohorts. Evidence tier "cohort-driver" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"CYLD" OR ABSTRACT:"CYLD" OR TITLE:"CYLD lysine 63 deubiquitinase" OR ABSTRACT:"CYLD lysine 63 deubiquitinase" OR TITLE:"Ubiquitin carboxyl-terminal hydrolase CYLD" OR ABSTRACT:"Ubiquitin carboxyl-terminal hydrolase CYLD" OR TITLE:"KIAA0849" OR ABSTRACT:"KIAA0849" OR TITLE:"USPL2" OR ABSTRACT:"USPL2" OR TITLE:"CYLD1" OR ABSTRACT:"CYLD1") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about CYLD, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetKAT6B
Shares Nasopharyngeal carcinoma, Breast cancer (all types), IntOGen, Prostate cancer.
- TargetCASP8
Shares Nasopharyngeal carcinoma, Bladder & urothelial cancer, Breast cancer (all types), IntOGen.
- TargetFAT1
Shares Nasopharyngeal carcinoma, Bladder & urothelial cancer, Breast cancer (all types), IntOGen.
- TargetSPEN
Shares Nasopharyngeal carcinoma, Renal cell carcinoma, Breast cancer (all types), IntOGen.
- TargetMYH11
Shares Nasopharyngeal carcinoma, Breast cancer (all types), IntOGen, Head and neck squamous cell carcinoma.
- TargetTET1
Shares Nasopharyngeal carcinoma, Renal cell carcinoma, IntOGen, Open Targets Platform.
- TargetZNF331
Shares Nasopharyngeal carcinoma, IntOGen, Open Targets Platform.
- TargetARID2
Shares Nasopharyngeal carcinoma, IntOGen, Head and neck squamous cell carcinoma, Open Targets Platform.